Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Pathway for Softgel vs Tablet Comparison [Design Issues]

posted by Obinoscopy – USA, 2018-05-15 21:04 (2967 d 04:49 ago) – Posting: # 18764
Views: 4,201

Dear bebac_fan,

❝ I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.

❝

I share the same view with you on this.

However I have a case where a BE study was conducted comparing Metronidazole tablet (Reference) with Metronidazole soft gel (test). Both were IR. Is this acceptable?

Regards,

—
Scopy

Complete thread:

Bioequivalence of IR vs MR tablet heritage 2018-05-05 06:25
- Consider 505(b)(2) Pathway bebac_fan 2018-05-05 17:08
  - Pathway for Softgel vs Tablet ComparisonObinoscopy 2018-05-15 19:04
    - Pathway for Softgel vs Tablet Comparison jag009 2018-05-18 16:33

Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
146 visitors (0 registered, 146 guests [including 25 identified bots]).
Forum time: 01:54 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas. Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz